Skip to main content
SpringerLink
Log in

Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153–1156.

    Article  CAS  PubMed  Google Scholar 

  2. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084–1089.

    Article  CAS  PubMed  Google Scholar 

  3. Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S . NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood 2006; 108: 3556–3559.

    Article  CAS  PubMed  Google Scholar 

  4. Stergianou K, Fox C, Russell NH . Fusion of NUP214 to ABL1 on amplified episomes in T-ALL—implications for treatment. Leukemia 2005; 19: 1680–1681.

    Article  CAS  PubMed  Google Scholar 

  5. De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O . Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia 2008, e-pub ahead of print.

  6. De Keersmaecker K, Porcu M, Gielen O, Cools J . LCK is a critical signaling effector in NUP214-ABL1 positive T-ALL. Haematologica 2008; 93 (s1) (abstract (0476)).

  7. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J et al. Activity of tyrosine kinase inhibitors against NUP214-ABL1-positive T cell malignancies. Leukemia 2008; 22: 1117–1124.

    Article  CAS  PubMed  Google Scholar 

  8. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands

    W Deenik, S C P A M van der Poel-van de Luytgaarde, P J M Valk & J J Cornelissen

  2. Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands

    H B Beverloo & M M Wattel

  3. Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands. E-mail: w.deenik@erasmusmc.nl,

    J W J van Esser

Authors
  1. W Deenik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H B Beverloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S C P A M van der Poel-van de Luytgaarde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M M Wattel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J W J van Esser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P J M Valk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J J Cornelissen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deenik, W., Beverloo, H., van der Poel-van de Luytgaarde, S. et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 23, 627–629 (2009). https://doi.org/10.1038/leu.2008.318

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.318

  • Springer Nature Limited

This article is cited by

Search

Navigation